ArticleCureus2025
Congenital Afibrinogenemia With Coexisting Factor V Leiden Mutation Complicated by Budd-Chiari Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital afibrinogenemia is a rare autosomal recessive bleeding disorder characterized by the complete absence of fibrinogen, a key protein in the coagulation cascade. Patients usually present with hemorrhagic manifestations, ranging from mild mucocutaneous bleeding to life-threatening events, such as intracranial or gastrointestinal hemorrhage. Paradoxically, thrombotic complications have been increasingly described, underscoring the dual nature of the disease. We report a case of a 15-year-old female with congenital afibrinogenemia who presented with abdominal pain and was diagnosed with Budd-Chiari syndrome (BCS), a rare but potentially fatal hepatic venous outflow obstruction. Genetic testing further revealed the presence of a heterozygous factor V Leiden mutation, a well-known inherited thrombophilia that likely contributed to the development of BCS in this patient. She was treated with fibrinogen replacement and anticoagulation therapy, with careful monitoring to balance bleeding and thrombotic risks. The patient showed clinical improvement and remained stable at three-month follow-up. The coexistence of a bleeding disorder and a prothrombotic mutation illustrates the complexity of clinical management, as therapeutic strategies must balance hemostatic replacement with anticoagulation while minimizing risks on both sides. This case highlights the need for heightened awareness of thrombotic complications in congenital afibrinogenemia, the importance of investigating concomitant thrombophilic risk factors, and the necessity of an individualized, multidisciplinary approach to optimize outcomes in rare coagulation disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.